Press Room
Dekkers: Pharma not appreciated by society
03/01/2012
Marijn Dekkers, chief executive at Bayer, has expressed his concerns about the pricing squeeze being put on innovative pharmaceutical groups whose efforts, he feels, are massively under-appreciated by society as a whole.
Support Defense Dept. Cancer Research
03/01/2012
Funding is under the umbrella of the Congressionally Directed Medical Research Programs and supports medical research for several forms of cancer, including kidney cancer.
FDA approves Inlyta for advanced kidney cancer
02/29/2012
The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
Role of lymph node dissection in RCC
02/29/2012
Controversy exists over whether lymph node dissection (LND) simply provides improved staging or whether removal of pathologic nodes offers a therapeutic advantage.
Axitinib Tops Sorafenib as Second-Line RCC Treatment
02/29/2012
Axitinib treatment led to a significant and clinically meaningful improvement in progression-free survival compared with sorafenib in patients with treatment-refractory renal-cell carcinoma...
Study: Bevacizumab in Combination With Low-Dose-Interferon
02/28/2012
This single arm study will assess progression free survival, tumor response and safety of Avastin in combination with interferon alfa-2a (IFN) as first line treatment in patients with metastatic clear cell renal cell carcinoma.
Partial Kidney Removal Also Gives Long-Term Survival: Study
02/24/2012
The study has revealed that usually the kidney cancer patients needing surgery have their whole kidney taken out but the patients can healthily survive long-term even if just a part of the organ is removed.
Pre-Surgical Sutent in Renal Cell Carcinoma
02/24/2012
The goal of this clinical research study is to learn if Sutent® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied.
News Feed| NeonCRM by Neon One |